Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04958785 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04958785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04958785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
December 14, 2021
Completion date
October 8, 2024
Enrollment
92 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer